Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation

Metabolism: Clinical and Experimental

Volumn 63, Issue 5, 2014, Pages 693-701

  Yang, Soo Jin ^a   Lim, Yunsook ^b  

^a Chonnam National University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Hepatic metaflammation; NLRP3 inflammasome; Non alcoholic fatty liver disease; Resveratrol; Sirtuin

Indexed keywords

CRYOPYRIN; GLUCOSE; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 6; LIVER PROTEIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RESVERATROL; SIRTUIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEPATIC METAFLAMMATION; HEPATITIS; IMMUNOPATHOLOGY; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIVER; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHAM FEEDING; SIGNAL TRANSDUCTION; SIRTUIN PATHWAY; TRIACYLGLYCEROL BLOOD LEVEL;

HEPATIC METAFLAMMATION; NLRP3 INFLAMMASOME; NON-ALCOHOLIC FATTY LIVER DISEASE; RESVERATROL; SIRTUIN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CARRIER PROTEINS; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; EATING; HEPATITIS; INFLAMMASOMES; LIVER; MALE; MICE; MICE, INBRED C57BL; ORGAN SIZE; STILBENES;

EID: 84899461863     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.02.003     Document Type: Article

References (46)

1. G. Tarantino, S. Savastano, and A. Colao Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance World J Gastroenterol 16 2010 4773 4783
2. M. Asrih, and F. Jornayvaz Inflammation as a link between nonalcoholic fatty liver disease and insulin resistance J Endocrinol 218 3 2013 R25 R36
3. M.R. Kashi, D.M. Torres, and S.A. Harrison Current and emerging therapies in nonalcoholic fatty liver disease Semin Liver Dis 28 2008 396 406
4. D.M. Torres, and S.A. Harrison Diagnosis and therapy of nonalcoholic steatohepatitis Gastroenterology 134 2008 1682 1698
5. A. Chuthan Sourianarayanane, M.R. Pagadala, and J.P. Kirwan Management of non-alcoholic fatty liver disease Minerva Gastroenterol Dietol 59 2013 69 87
6. J.K. Dowman, M.J. Armstrong, J.W. Tomlinson, and P.N. Newsome Current therapeutic strategies in non-alcoholic fatty liver disease Diabetes Obes Metab 13 2011 692 702
7. H. Tilg, and A. Moschen Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease Minerva Gastroenterol Dietol 56 2010 159 167
8. E.M. McCarthy, and M.E. Rinella The role of diet and nutrient composition in nonalcoholic fatty liver disease J Acad Nutr Diet 112 2012 401 409
9. J. Ahn, H. Lee, C.H. Jung, and T. Ha Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet Mol Nutr Food Res 56 2012 1665 1674
10. J. Xiao, C.T. Ho, E.C. Liong, A.A. Nanji, and T.M. Leung et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways Eur J Nutr 53 2014 187 199
11. Y. Liu, D. Wang, D. Zhang, Y. Lv, Y. Wei, and W. Wu et al. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro J Agric Food Chem 59 2011 12254 12263
12. M.M. Poulsen, J.O. Larsen, S. Hamilton-Dutoit, B.F. Clasen, N. Jessen, and S.K. Paulsen et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet Nutr Res 32 2012 701 708
13. E. Fuentes, F. Fuentes, G. Vilahur, L. Badimon, and I. Palomo Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome Mediators Inflamm 2013 2013 136584
14. V.R. Richardson, K.A. Smith, and A.M. Carter Adipose tissue inflammation: feeding the development of type 2 diabetes mellitus Immunobiology 218 2013 1497 1504
15. M.E. Ramos-Nino The role of chronic inflammation in obesity-associated cancers ISRN Oncol 2013 2013 697521
16. K. Schroder, and J. Tschopp The inflammasomes Cell 140 2010 821 832
17. K. Schroder, R. Zhou, and J. Tschopp The NLRP3 inflammasome: a sensor for metabolic danger? Science 327 2010 296 300
18. B. Vandanmagsar, Y.H. Youm, A. Ravussin, J.E. Galgani, K. Stadler, and R.L. Mynatt et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance Nat Med 17 2011 179 188
19. A. Wree, A. Eguchi, M.D. McGeough, C.A. Pena, C.D. Johnson, and A. Canbay et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis Hepatology 59 2014 898 910
20. P. Signorelli, and R. Ghidoni Resveratrol as an anticancer nutrient: molecular basis, open questions and promises J Nutr Biochem 16 2005 449 466
21. J.M. Wu, T.C. Hsieh, and Z. Wang Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues Am J Cardiovasc Dis 1 2011 38 47
22. J.M. Wu, and T.C. Hsieh Resveratrol: a cardioprotective substance Ann N Y Acad Sci 1215 2011 16 21
23. A.A. Bertelli, and D.K. Das Grapes, wines, resveratrol, and heart health J Cardiovasc Pharmacol 54 2009 468 476
24. P. Brasnyó, G.A. Molnár, M. Mohás, L. Markó, B. Laczy, and J. Cseh et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients Br J Nutr 106 2011 383 389
25. C.E. Park, M.J. Kim, J.H. Lee, B.I. Min, H. Bae, and W. Choe et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase Exp Mol Med 39 2007 222 229
26. S. Sharma, C.S. Misra, S. Arumugam, S. Roy, V. Shah, and J.A. Davis et al. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes Phytother Res 25 2011 67 73
27. W. Kang, H.J. Hong, J. Guan, D.G. Kim, E.J. Yang, and G. Koh et al. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents Metabolism 61 2012 424 433
28. T. Szkudelski, and K. Szkudelska Anti-diabetic effects of resveratrol Ann N Y Acad Sci 1215 2011 34 39
29. X. Hou, S. Xu, K.A. Maitland-Toolan, K. Sato, B. Jiang, and Y. Ido et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase J Biol Chem 283 2008 20015 20026
30. M.C. Haigis, and D.A. Sinclair Mammalian sirtuins: biological insights and disease relevance Annu Rev Pathol 5 2010 253 295
31. A. Hill, S. Geißler, M. Meyring, S. Hecht, M. Weigandt, and K. Mäder et al. In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps Int J Pharm 451 2013 57 66
32. J. Yoshino, C. Conte, L. Fontana, B. Mittendorfer, S. Imai, and K.B. Schechtman et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance Cell Metab 16 2012 658 664
33. C.C. Chang, C.Y. Chang, Y.T. Wu, J.P. Huang, T.H. Yen, and L.M. Hung Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase J Biomed Sci 18 2011 47
34. M. Kitada, and D. Koya SIRT1 in type 2 diabetes: mechanisms and therapeutic potential Diabetes Metab J 37 2013 315 325
35. J. Zheng, L.L. Chen, H.H. Zhang, X. Hu, W. Kong, and D. Hu Resveratrol improves insulin resistance of catch-up growth by increasing mitochondrial complexes and antioxidant function in skeletal muscle Metabolism 61 2012 954 965
36. L.L. Chen, H.H. Zhang, J. Zheng, X. Hu, W. Kong, and D. Hu et al. Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation Metabolism 60 2011 1598 1609
37. J.M. Bruun, A.S. Lihn, C. Verdich, S.B. Pedersen, S. Toubro, and A. Astrup et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans Am J Physiol Endocrinol Metab 285 2003 E527 E533
38. P.A. Kern, G.B. Di Gregorio, T. Lu, N. Rassouli, and G. Ranganathan Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression Diabetes 52 2003 1779 1785
39. M.C. Wulster-Radcliffe, K.M. Ajuwon, J. Wang, J.A. Christian, and M.E. Spurlock Adiponectin differentially regulates cytokines in porcine macrophages Biochem Biophys Res Commun 316 2004 924 929
40. G.L. Wang, Y.C. Fu, W.C. Xu, Y.Q. Feng, S.R. Fang, and X.H. Zhou Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway Biochem Biophys Res Commun 380 2009 644 649
41. S.J. Cho, U.J. Jung, and M.S. Choi Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice Br J Nutr 108 2012 2166 2175
42. J.C. Pickup, M.B. Mattock, G.D. Chusney, and D. Burt NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X Diabetologia 40 1997 1286 1292
43. L.J. Dixon, M. Berk, S. Thapaliya, B.G. Papouchado, and A.E. Feldstein Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis Lab Invest 92 2012 713 723
44. T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, and G. Szabo Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells Hepatology 54 2011 133 144
45. G. Szabo, and T. Csak Inflammasomes in liver diseases J Hepatol 57 2012 642 654
46. S. Timmers, M.K. Hesselink, and P. Schrauwen Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 1290 2013 83 89